Belluscura plc
("Belluscura" or the "Group")
Result of Annual General Meeting
LONDON, U.K. AND PLANO, TX, U.S. (30 June 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that at its Annual General Meeting held today, 30 June 2021, all the resolutions put to shareholders were passed. Resolutions 1 to 6 were passed as ordinary resolutions and Resolutions 7 and 8 were passed as special resolutions.
The final proxy voting position is shown below. Any proxy votes which are at the discretion of the Chairman have been included in the "For" total.
|
No. |
Resolutions (Please refer to Notice of Meeting for full text) |
For |
Against |
Vote Withheld |
% Vote Cast For[1] |
|
Ordinary Resolutions |
|||||
|
1. |
To adopt the audited accounts of the Company for the period ended 31 December 2020. |
50,496,815 |
0 |
0 |
100% |
|
2. |
To re-elect Robert Rauker as a Director of the Company. |
50,496,815 |
0 |
0 |
100% |
|
3. |
To re-elect Anthony Dyer as a Director of the Company. |
50,496,815 |
0 |
0 |
100% |
|
4. |
To re-appointed KPMG LLP as auditor to the Company. |
50,495,815 |
1,000 |
0 |
99.998% |
|
5. |
To authorise the Directors to determine the remuneration of the auditors. |
50,495,815 |
1,000 |
0 |
99.998% |
|
6. |
Authority to Allot Shares. |
50,495,815 |
1,000 |
0 |
99.998% |
|
Special Resolutions |
|||||
|
7. |
Disapplication of Statutory Pre-Emption Rights. |
49,329,149 |
1,167,666 |
0 |
97.688% |
|
8. |
Authority to Purchase Own Shares. |
50,496,815 |
0 |
0 |
100% |
For further information please contact:
|
Belluscura plc |
|
|
Robert Rauker, Chief Executive Officer |
via Walbrook PR |
|
Anthony Dyer, Chief Financial Officer |
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD) |
Tel: +44 (0)20 3368 3550 |
|
Neil Baldwin |
|
|
|
|
|
Dowgate Capital Limited (Broker) |
Tel: +44 (0)20 3903 7715 |
|
James Serjeant / Nicholas Chambers |
|
|
|
|
|
Walbrook PR Ltd (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com |
|
Paul McManus / Sam Allen |
Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 |
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
Belluscura is listed on the AIM market of the London Stock Exchange (AIM: BELL).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
